Ubs Group Ag Vallon Pharmaceuticals, Inc. Transaction History

Ubs Group Ag

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$0.27 - $0.88 $4,705 - $15,336	-17,428 Reduced 85.65%	2,919 $1,000
Q4 2022 Feb 08, 2023	BUY	$0.22 - $0.52 $4,476 - $10,580	20,347 New	20,347 $5,000
Q2 2022 Aug 10, 2022	SELL	$0.42 - $2.27 $3,693 - $19,962	-8,794 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$1.79 - $8.0 $10,799 - $48,264	6,033 Added 218.51%	8,794 $17,000
Q4 2021 Feb 14, 2022	BUY	$4.02 - $7.3 $5,077 - $9,219	1,263 Added 84.31%	2,761 $17,000
Q3 2021 Nov 15, 2021	BUY	$3.85 - $9.68 $2,637 - $6,630	685 Added 84.26%	1,498 $11,000
Q2 2021 Aug 13, 2021	BUY	$3.66 - $5.83 $2,975 - $4,739	813 New	813 $4,000

Ticker VLON
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 10,512,800
Description
Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medications for central nervous system disorders with a focus on abuse-deterrent medications. Its lead investigational product candidate is ADAIR, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the ...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.